Drug Profile
Amantadine/oseltamivir/ribavirin - Adamas Pharmaceuticals
Alternative Names: ADS-8902; Amantadine/ribavirine/oseltamivir; Oseltamivir/amantadine/ribavirin; Oseltamivir/ribavirin/amantadine; Ribavirin/amantadine/oseltamivir; Ribavirin/oseltamivir/amantadineLatest Information Update: 02 Dec 2021
Price :
$50
*
At a glance
- Originator Adamas Pharmaceuticals
- Developer Adamas Pharmaceuticals; National Institutes of Health (USA)
- Class Acetamides; Adamantanes; Antivirals; Cyclohexenes; Esters; Furans; Organic bridged compounds; Ribonucleosides; Small molecules; Triazoles
- Mechanism of Action Dopamine receptor agonists; Ion channel modulators; Neuraminidase inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza A virus H1N1 subtype; Influenza A virus infections
Most Recent Events
- 24 Nov 2021 Adamas Pharmaceuticals has been acquired by Supernus Pharmaceuticals
- 14 Sep 2017 Chemical structure information added
- 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Canada (PO)